The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results